Twist Bioscience (NASDAQ:TWST) Trading Down 5.4% - What's Next?

Key Points

• Twist Bioscience's stock declined by 5.4% during trading on Tuesday, closing at $24.83, with significant lower trading volume compared to average.
• The company reported a quarterly earnings per share (EPS) of (0.47), exceeding expectations, and has a consensus target price of $49.40 from analysts.
• Insider selling occurred recently, with CEO Emily M. Leproust and CFO Adam Laponis selling a total of 5,250 shares, while institutional investors have been increasing their stakes in the company.

Twist Bioscience Corporation (NASDAQ:TWST - Get Free Report) fell 5.4% during trading on Tuesday . The stock traded as low as $24.44 and last traded at $24.83. 486,227 shares traded hands during trading, a decline of 59% from the average session volume of 1,194,919 shares. The stock had previously closed at $26.25.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on TWST. Cowen reaffirmed a "buy" rating on shares of Twist Bioscience in a research report on Monday, August 4th. Evercore ISI set a $46.00 price target on Twist Bioscience in a research note on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $49.40.

Twist Bioscience Price Performance

The company has a 50 day moving average price of $31.53 and a 200 day moving average price of $34.61. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.90 and a quick ratio of 3.60. The firm has a market cap of $1.49 billion, a PE ratio of -16.98 and a beta of 2.31.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.07. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. The company had revenue of $96.06 million for the quarter, compared to analysts' expectations of $95.52 million. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Sell-side analysts expect that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Insider Buying and Selling

In other Twist Bioscience news, CEO Emily M. Leproust sold 1,678 shares of the business's stock in a transaction dated Friday, June 20th. The stock was sold at an average price of $35.76, for a total transaction of $60,005.28. Following the completion of the sale, the chief executive officer owned 645,782 shares of the company's stock, valued at approximately $23,093,164.32. The trade was a 0.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Adam Laponis sold 2,449 shares of the business's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the transaction, the chief financial officer owned 103,569 shares in the company, valued at approximately $3,951,157.35. This trade represents a 2.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,250 shares of company stock worth $193,852 in the last ninety days. 3.01% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Twist Bioscience

Several institutional investors have recently modified their holdings of TWST. Stifel Financial Corp grew its holdings in shares of Twist Bioscience by 19.6% in the 4th quarter. Stifel Financial Corp now owns 8,331 shares of the company's stock worth $387,000 after acquiring an additional 1,364 shares during the last quarter. Northern Trust Corp lifted its stake in Twist Bioscience by 9.0% during the fourth quarter. Northern Trust Corp now owns 627,649 shares of the company's stock valued at $29,167,000 after buying an additional 51,926 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in shares of Twist Bioscience by 138.0% in the fourth quarter. BNP Paribas Financial Markets now owns 90,527 shares of the company's stock worth $4,207,000 after buying an additional 52,495 shares during the period. Cetera Investment Advisers purchased a new position in shares of Twist Bioscience in the fourth quarter worth approximately $220,000. Finally, Deutsche Bank AG raised its holdings in shares of Twist Bioscience by 8.8% during the fourth quarter. Deutsche Bank AG now owns 159,752 shares of the company's stock valued at $7,424,000 after acquiring an additional 12,940 shares during the period.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.